Collectively, these results suggest that Y1 antagonism preserves insulin action during early-stage diabetes while improving β-cell secretory capacity postprandially during late-stage diabetes, thereby improving the diabetic condition in db/db mice. Here, INS is linked to diabetes mellitus.